OTCQB: PHRRF | CSE: PHRM
PharmaTher Holdings Ltd. Ketamine
  • HOME
  • COMPANY
    • Management
    • Board Of Directors
  • PRODUCTS
    • KetaVault
    • KETARX Ketamine
  • INVESTORS
  • NEWS
  • CONTACT
  • HOME
  • COMPANY
    • Management
    • Board Of Directors
  • PRODUCTS
    • KetaVault
    • KETARX Ketamine
  • INVESTORS
  • NEWS
  • CONTACT

Press Releases

2/7/2023

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System

 

Read More

2/2/2023

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to  KETARX™ (Ketamine) for the Treatment of Rett Syndrome

 

Read More

2/1/2023

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease

 

Read More

    Archives

    May 2025
    March 2025
    February 2025
    January 2025
    November 2024
    October 2024
    September 2024
    August 2024
    May 2024
    April 2024
    February 2024
    January 2024
    September 2023
    July 2023
    June 2023
    May 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020

    Categories

    All

    RSS Feed

Psychedelic Pharmaceuticals
© COPYRIGHT 2025.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.